• Phone FeatureAndroid客户端
  • Phone FeatureIOS客户端
  • Phone Feature微信小程序
  • Phone FeatureH5页面
  • 1
    返回

    Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial

    10.1111/dom.14107
    2020-06-22
    6
    OA
    PDF
    AI
    收藏
    分享
    原文链接
    查看原文
    摘要

    摘要

    En 中文
    Aim To determine the glucose-independent effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin versus the sulphonylurea glimepiride on systemic haemodynamics in the fasting and postprandial state in patients with type 2 diabetes (T2D). Materials and Methods In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. In a sub-study involving 26 patients, systemic haemodynamics were also assessed following a standardized liquid meal (Nutridrink Yoghurt style). Systemic haemodynamics (oscillometric device and finger photoplethysmography), arterial stiffness (applanation tonometry) and cardiac sympathovagal balance (heart rate variability [HRV]) were measured in the fasting state and repetitively following the meal. Ewing tests were performed in the fasting state. Results From baseline to week 8, linagliptin compared with glimepiride did not affect systemic haemodynamics, arterial stiffness or HRV in the fasting state. Linagliptin increased parasympathetic nervous activity, as measured by the Valsalva manoeuvre (P= .021) and deep breathing test (P =.027) compared with glimepiride. Postprandially, systolic blood pressure (SBP) dropped an average of 7.6 +/- 1.6 mmHg. Linagliptin reduced this decrease to 0.7 +/- 2.3 mmHg, which was significant to glimepiride (P= .010). Conclusions When compared with glimepiride, linagliptin does not affect fasting blood pressure. However, linagliptin blunted the postprandial drop in SBP, which could benefit patients with postprandial hypotension.
    关键词:
    DPP-4 inhibitor
    glimepiride
    haemodynamics
    heart rate
    linagliptin
    sulphonylurea
    sympathetic nervous system
    type 2 diabetes
    AI总结

    AI总结

    对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

    期刊

    期刊

    D
    IF:
    5.7
    论文数: 6.1K
    被引数: 1.7W
    学者

    学者

    J
    Jordan M. Kraaijenhof
    H 指数:
    11
    论文数: 39
    被引数: 590
    M
    Muskiet, Marcel H. A.
    H 指数:
    31
    论文数: 112
    被引数: 4.8K
    T
    Tonneijck, Lennart
    H 指数:
    0
    论文数: 4
    被引数: 0
    O
    Ouwens, D. Margriet
    H 指数:
    0
    论文数: 4
    被引数: 0
    K
    Kramer, Mark H. H.
    H 指数:
    0
    论文数: 15
    被引数: 0
    学者 查看更多内容
    机构

    机构

    U
    university of amsterdam
    学者数:
    5.8W
    论文数: 5.0W
    被引数: 47
    H
    Heinrich Heine University Dusseldorf
    学者数:
    1.8W
    论文数: 1.4W
    被引数: 117
    引用论文

    引用论文

    被引论文

    被引论文